In a collaboration potentially valued at $1.9 billion, Amgen is teaming up with Cambridge, Mass.-based Generate Biomedicines to develop protein therapeutics for up to five clinical targets.
Source: Drug Industry Daily
In a collaboration potentially valued at $1.9 billion, Amgen is teaming up with Cambridge, Mass.-based Generate Biomedicines to develop protein therapeutics for up to five clinical targets.
Source: Drug Industry Daily